Dmitry Samarsky, PhD
Dmitry Samarsky, PhD
Executive Vice President of Technology and Business Development, RiboBio, China
Dmitry Samarsky earned his PhD in biochemistry and molecular biology at University of Massachusetts, Amherst, and from 1998 to 2001 he held H. Arthur Smith Fellowship for Cancer Research at Dr. Michael Green’s laboratory, HHMI/University of Massachusetts Medical School. From 2001 to 2007 Dr. Samarsky was developing oligonucleotide-based technologies at Sequitur/Invitrogen and Dharmacon/ThermoFisher. Most recently, he was carrying responsibilities for technology and business development at RXi Pharma (2007-2011) and RiboBio Co (2011-present), biopharmaceutical companies developing oligonucleotide-based technologies and therapeutics. Dr. Samarsky co-authored numerous research articles, reviews and book chapters, as well as patents and patent applications. He is a Distinguished Editor for Journal of RNAi and Gene Silencing, and served as advisor, session chair and speaker at more than hundred of scientific conferences around the world.